CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES >

2020 , Vol. 38 >Issue 3: 370 - 377

DOI: https://doi.org/10.12140/j.issn.1000-7423.2020.03.018

REVIEWS

Research progress on combined medications for schistosomiasis

  • Jin-ying ZHAO ,
  • Peng LIU ,
  • Yan-wei LI ,
  • Shi-ping WANG
Expand
  • 1 Key Laboratory of Molecular Biology Diagnosis, Shaoyang University, Shaoyang 422000, China
    2 Department of Human Anatomy and Histology and Embryology, Basic Medical College, Shaoyang College, Shaoyang 422000, China
    3 Department of Pathogenic Biology, Xiangya School of Medicine, Central South University, Changsha 410013, China

Received date: 2019-08-16

  Online published: 2020-07-07

Supported by

Research Project of the Education Department of Hunan Province(16C1439)

Fold

Abstract

Currently, the praziquantel (PZQ) remains the drug of choice for schistosomiasis treatment. Despite its effectiveness in killing adult schistosomes, PZQ is ineffective for schistosomula, and monotherapy using PZQ cannot reverse the pathological damage associated with the infection. With the emerging PZQ-resistant strains, it is imperative to find out alternatives for PZQ. At present, the research and development of new anti-schistosomiasis drugs is moving slowly, but pre-clinical and clinical trials found that combined medication of PZQ and various antimalarial drugs has shown good schistosomicidal effects. Also, synergistic effects have been exerted by combined use of PZQ and auxiliary drugs in the treatment of schistosomiasis. This article provides a review on the research progress in this field.

Key words： Schistosomiasis; Praziquantel; Antimalarials; Anti-fibrosis; Antioxidants

Cite this article

Jin-ying ZHAO , Peng LIU , Yan-wei LI , Shi-ping WANG . Research progress on combined medications for schistosomiasis[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2020 , 38(3) : 370 -377 . DOI: 10.12140/j.issn.1000-7423.2020.03.018

References

[1] Colley DG, Bustinduy AL, Secor WE, et al. Human schistosomiasis[J]. Lancet, 2014,383(9936):2253-2264.
[2] Caffrey CR. Chemotherapy of schistosomiasis: present and future[J]. Curr Opin Chem Biol, 2007,11(4):433-439.
[3] M?der P, Rennar GA, Ventura AMP, et al. Chemotherapy for fighting schistosomiasis: past, present and future[J]. Chem Med Chem, 2018,13(22):2374-2389.
[4] Xiao SH. Study progress on the mode of action of praziquantel against schistosomes[J]. Chin J Parasitol Parasit Dis, 2007,25(6):492-502. (in Chinese)
[4] ( 肖树华. 吡喹酮抗血吸虫作用的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2007,25(6):492-502.)
[5] Vale N, Gouveia MJ, Rinaldi G, et al. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance[J]. Antimicrob Agents Chemother, 2017,61(5). e02582-e02598.
[6] da Silva VBR, Campos BRKL, de Oliveira JF, et al. Medicinal chemistry of antischistosomal drugs: praziquantel and oxamniquine[J]. Bioorg Med Chem, 2017,25(13):3259-3277.
[7] Valentim CLL, Cioli D, Chevalier FD, et al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites[J]. Science, 2013,342(6164):1385-1389.
[8] Shaw JR, Brammer KW. The treatment of experimental schistosomiasis with a combination of oxamniquine and praziquantel[J]. Trans Royal Soc Trop Med Hyg, 1983,77(1):39-40.
[9] Botros S, Soliman A, El-Gawhary N, et al. Effect of combined low dose praziquantel and oxamniquine on different stages of schistosome maturity[J]. Trans Royal Soc Trop Med Hyg, 1989,83(1):86-89.
[10] Delgado VS, Suarez DP, Cesari IM, et al. Experimental chemotherapy of Schistosoma mansoni with praziquantel and oxamniquine: differential effect of single or combined formulations of drugs on various strains and on both sexes of the parasite[J]. Parasitol Res, 1992,78(8):648-654.
[11] Pugh RN, Teesdale CH. Synergy of concurrent low dose oxamniquine and praziquantel in schistosomiasis[J]. BMJ, 1983,287(6396):877-878.
[12] Creasey AM, Taylor P, Thomas JE. Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean school children[J]. Cent Afr J Med, 1986,32(7):165-167.
[13] Shuhua X, Hotez PJ, Tanner M. Artemether, an effective new agent for chemoprophylaxis against shistosomiasis in China: its in vivo effect on the biochemical metabolism of the Asian schistosome[J]. Southeast Asian J Trop Med Public Health, 2000,31(4):724-732.
[14] El-Lakkany NM, Seif el-Din SH. Haemin enhances the in vivo efficacy of artemether against juvenile and adult Schistosoma mansoni in mice[J]. Parasitol Res, 2013,112(5):2005-2015.
[15] Pérez del Villar L, Burguillo FJ, López-Abán J, et al. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis[J]. PLoS One, 2012,7(9):e45867.
[16] Xiao SH, You JQ, Mei JY, et al. Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits[J]. Parasitol Int, 2000,49(1):25-30.
[17] Utzinger J, Chollet J, You JQ, et al. Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals[J]. Acta Trop, 2001,80(1):9-18.
[18] Mahmoud MR, Botros SS. Artemether as adjuvant therapy to praziquantel in murine Egyptian schistosomiasis mansoni[J]. J Parasitol, 2005,91(1):175-178.
[19] Hou XY, McManus DP, Gray DJ, et al. A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China[J]. Bull World Health Organ, 2008,86(10):788-795.
[20] Abdin AA, Ashour DS, Shoheib ZS. Artesunate effect on schistosome thioredoxin glutathione reductase and cytochrome c peroxidase as new molecular targets in Schistosoma mansoni-infected mice[J]. Biomed Environ Sci, 2013,26(12):953-961.
[21] Clercq D, Vercruysse J, Verle P, et al. What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections?[J]. Trop Med Int Health, 2000,5(10):744-746.
[22] Inyang-Etoh PC, Ejezie GC, Useh MF, et al. Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria[J]. Trans Royal Soc Trop Med Hyg, 2009,103(1):38-44.
[23] Yunusa EU, Awosan KJ, Ibrahim MTO, et al. Comparative cure rates of artesunate-praziquantel combination and praziquantel monotherapy in the control of urinary schistosomiasis among “Almajiri” school children in Sokoto, Nigeria.[J]. Int Res J Basic Clin Stud, 2016,5:5-9.
[24] Sissoko MS, Dabo A, Traoré H, et al. Efficacy of artesunate +sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children[J]. PLoS One, 2009,4(10):e6732.
[25] Wang JY, Ding DB, Li GF, et al. Therapeutic efficacy of naphthoquine phosphate combined with artemisinine against Plasmodium knowlesi[J]. Chin J Parasitol Parasit Dis, 2008,26(6):442-444. (in Chinese)
[25] ( 王京燕, 丁德本, 李国福, 等. 磷酸萘酚喹伍用青蒿素对猴疟原虫的药效学研究[J]. 中国寄生虫学与寄生虫病杂志, 2008,26(6):442-444.)
[26] El-Beshbishi SN, Taman A, El-Malky M, et al. First insight into the effect of single oral dose therapy with artemisinin-naphthoquine phosphate combination in a mouse model of Schistosoma mansoni infection[J]. Int J Parasitol, 2013,43(7):521-530.
[27] Van Nassauw L, Toovey S, Van Op den Bosch J, et al. Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice[J]. Travel Med Infect Dis, 2008,6(5):253-258.
[28] Xiao SH, Xue J. Study progress on mefloquine against schistosomes and other helminths[J]. Chin J Parasitol Parasit Dis, 2012,30(2):131-138, 145. (in Chinese)
[28] ( 肖树华, 薛剑. 甲氟喹抗血吸虫及其他蠕虫作用的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2012,30(2):131-138, 145.)
[29] Xiao SH, Mei JY, Jiao PY. Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum[J]. Parasitol Res, 2011,108(2):399-406.
[30] Keiser J, Manneck T, Vargas M. Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro[J]. J Antimicrob Chemother, 2011,66(8):1791-1797.
[31] Nashwa SA, Naglaa SA. Evaluation of mefloquine-praziquantel combination therapy in pre-patent and patent Schistosoma mansoni infection in mice[J]. Sci Parasitol, 2011,12(3):139-149.
[32] Keiser J, N′Guessan NA, Adoubryn KD, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial[J]. Clin Infect Dis, 2010,50(9):1205-1213.
[33] Keiser J, Silué KD, Adiossan LK, et al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial[J]. PLoS Negl Trop Dis, 2014,8(7):e2975.
[34] Mossallam SF, Amer EI, El-Faham MH. Efficacy of Synriam?, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of Schistosoma mansoni[J]. Acta Trop, 2015,143:36-46.
[35] Portela J, Boissier J, Gourbal B, et al. Antischistosomal activity of trioxaquines: in vivo efficacy and mechanism of action on Schistosoma mansoni[J]. PLoS Negl Trop Dis, 2012,6(2):e1474.
[36] El Kouni MH, Diop D, O′Shea P, et al. Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5′-monophosphate for the treatment of schistosomiasis[J]. Antimicrob Agents Chemother, 1989,33(6):824-827.
[37] El Kouni MH, Knopf PM, Cha S. Combination therapy of Schistosoma japonicum by tubercidin and nitrobenzylthioinosine 5′-monophosphate[J]. Biochem Pharmacol, 1985,34(21):3921-3923.
[38] El Kouni MH, Messier NJ, Cha S. Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors[J]. Biochem Pharmacol, 1987,36(22):3815-3821.
[39] Sulaiman SM, Ali HM, Homeida MM, et al. Efficacy of a new Hoffmann-La Roche compound (Ro 15-5458) against Schistosoma mansoni (Gezira strain, Sudan) in vervet monkeys (Cercopithecus aethiops)[J]. Trop Med Parasitol, 1989,40(3):335-336.
[40] Mahmoud M, Zoheiry M, Nosseir M. Effect of combined chemotherapy and anti-inflammatory drugs on murine schistosomiasis[J]. Arzneimittelforschung, 2011,52(4):294-301.
[41] Yepes E, Varela-M RE, López-Abán J, et al. Inhibition of granulomatous inflammation and prophylactic treatment of schistosomiasis with a combination of edelfosine and praziquantel[J]. PLoS Negl Trop Dis, 2015,9(7):e0003893.
[42] Yepes E, Varela-M RE, López-Abán J, et al. In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine[J]. PLoS One, 2014,9(10):e109431.
[43] Hassan S, Ali I, Nessim N, et al. Treatment of acute Schistosomiasis mansoni with praziquantel and an antifibrotic agent in mice[J]. Arzneimittelforschung, 2011,53(6):440-444.
[44] Botros S, Mahmoud M, Hammam O, et al. Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates[J]. Apmis, 2006,114(7/8):480-491.
[45] Soliman MFM, Ibrahim MM. Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on Schistosoma haematobium harboured in hamster: surface ultrastructure and parasitological study[J]. Acta Trop, 2005,93(1):1-9.
[46] Chen GZ, Foster L, Bennett J. Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaryl-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival[J]. Naunyn-Schmiedeberg’s Arch Pharmacol, 1990,342(4):477-482.
[47] Rojo-Arreola L, Long T, Asarnow D, et al. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis[J]. PLoS One, 2014,9(1):e87594.
[48] Rizk M, Ibrahim N, El-Rigal N. Comparative in vivo antioxidant levels in Schistosoma mansoni infected mice treated with praziquantel or the essential oil of Melaleuca armillaris leaves[J]. Pak J Biol Sci, 2012,15(20):971-978.
[49] De Oliveira RN, Rehder VLG, Santos Oliveira AS, et al. Schistosoma mansoni: in vitro schistosomicidal activity of essential oil of Baccharis trimera (less) DC[J]. Exp Parasitol, 2012,132(2):135-143.
[50] Elsammak MY, Al-Sharkaweey RM, Ragab MS, et al. IL-4 and reactive oxygen species are elevated in Egyptian patients affected with schistosomal liver disease[J]. Parasite Immunol, 2008,30(11-12):603-609.
[51] McCormick ML, Metwali A, Railsback MA, et al. Eosinophils from schistosome-induced hepatic granulomas produce superoxide and hydroxyl radical[J]. J Immunol, 1996,157(11):5009-5015.
[52] Soliman RH, Ismail OA, Badr MS, et al. Resveratrol ameliorates oxidative stress and organ dysfunction in Schistosoma mansoni infected mice[J]. Exp Parasitol, 2017,174:52-58.
[53] De Paula AD, Brunetto MMM, Rezende ME, et al. Curcumin generates oxidative stress and induces apoptosis in adult Schistosoma mansoni worms[J]. PLoS One, 2016,11(11):e0167135.
[54] Kamel ROA, El-Shinnawy NA. Immunomodulatory effect of garlic oil extract on Schistosoma mansoni infected mice[J]. Asian Pac J Trop Med, 2015,8(12):999-1005.
[55] De Lima AA, de Azevedo AMC, Silva RA, et al. Immunohistopathological changes in murine Schistosomiasis mansoni under the influence of N-acetyl-L-cysteine[J]. Parasitol Res, 2012,111(4):1569-1578.
Options
Outlines

/

〈 〉